Different Strategies Targeting Gut Microbiota for the Management of
Several Disorders: A Sustainable Approach

Mahima      Chowdhury; Neil      Raj Chaudhary; Paranjeet      Kaur; Anju      Goyal; Sanjeev Kumar      Sahu

doi:10.2174/0118715265267536231121095634

Abstract

Background: A potential limelight is flashed on the Gut Microbiota (GM) in the human body, which confers additional psychological as well as physiological attributes to health. Other than just occupying a wide portion of the gastrointestinal tract, it also plays numerous functions in the systems of the body. Gut Microbiota is largely responsible for a considerably vast array of conditions such as obesity, diabetes ,other metabolic disorders, and cardiovascular disorders. Strategies targeting the gut microbiota have been proposed as a promising approach for the management of these disorders.

Objective: This review aims to summarize the different strategies targeting the gut microbiota for the management of several disorders and to highlight the importance of a sustainable approach.

Methods: A comprehensive literature search was conducted using various databases between 2008 and 2022 that focused on the use of prebiotics, probiotics, synbiotics, postbiotics, fecal microbiota transplantation, dietary interventions, and antibiotics.

Results: Different strategies targeting the gut microbiota for the management of several disorders were identified, including probiotics, prebiotics, synbiotics, postbiotics, fecal microbiota transplantation, and dietary interventions. Modification in diet and lifestyle, allowing favorable microbiota growth in the stomach, intake of prebiotics and probiotics, and fecal microbiota transplantation are amongst the widely accepted recent approaches allowing the application of GM in the field of treatment.

Conclusion: Although considerable steps in enhancing and understanding the mechanism of treatment with the help of gut microbiota are under progress, much diversified and elaborate research must be conducted in order to enhance and implement the use of GM with high effectiveness.

Graphical Abstract

[1]
Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ  2018; 361: k2179.
 [http://dx.doi.org/10.1136/bmj.k2179] [PMID:  29899036]

[2]
Choices EFH. What is the role of gut bacteria in human health? EUFIC  2013. Available from:
          https://www.eufic.org/en/healthy-living/article/the-role-of-gut-microorganisms-in-human-health (Accessed on 25-08-2022). 

[3]
Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol  2015; 21(29): 8787-803.
 [http://dx.doi.org/10.3748/wjg.v21.i29.8787] [PMID:  26269668]

[4]
Zhang S, Cai Y, Meng C, et al. The role of the microbiome in diabetes mellitus. diabetes research and clinical practice   2021; 172: 108645.

[5]
Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol  2015; 31(1): 69-75.
 [http://dx.doi.org/10.1097/MOG.0000000000000139] [PMID:  25394236]

[6]
Fredricks D N.  The human microbiota: How microbial communities affect health and disease. 2013.
 [http://dx.doi.org/10.1002/9781118409855]

[7]
Seekatz AM, Aas J, Gessert CE, et al. Recovery of the gut microbiome following fecal microbiota transplantation. MBio  2014; 5(3): e00893-14.
 [http://dx.doi.org/10.1128/mBio.00893-14] [PMID:  24939885]

[8]
Gurung M, Li Z, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology EBioMedicine. Elsevier BV 2020.

[9]
Novakovic M, Rout A, Kingsley T, et al. Role of gut microbiota in cardiovascular diseases. World J Cardiol  2020; 12(4): 110-22.
 [http://dx.doi.org/10.4330/wjc.v12.i4.110] [PMID:  32431782]

[10]
Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol  2015; 28(2): 203-9.
 [PMID:  25830558]

[11]
Liao DH, Zhao JB, Gregersen H. Gastrointestinal tract modelling in health and disease. World J Gastroenterol  2009; 15(2): 169-76.
 [http://dx.doi.org/10.3748/wjg.15.169] [PMID:  19132766]

[12]
Cheng LK, O’Grady G, Du P, Egbuji JU, Windsor JA, Pullan AJ. Gastrointestinal system. Wiley Interdiscip Rev Syst Biol Med  2010; 2(1): 65-79.
 [http://dx.doi.org/10.1002/wsbm.19] [PMID:  20836011]

[13]
Jovel J, Dieleman LA, Kao D, Mason AL, Wine E. The human gut microbiome in health and disease. Metagenomics  2018; 197-213.

[14]
Chen Y, Zhou J, Wang L. Role and mechanism of gut microbiota in human disease. Front Cell Infect Microbiol  2021; 11: 625913.
 [http://dx.doi.org/10.3389/fcimb.2021.625913] [PMID:  33816335]

[15]
Sun P, Su L, Zhu H, et al. Gut microbiota regulation and their implication in the development of neurodegenerative disease. Microorganisms  2021; 9(11): 2281.
 [http://dx.doi.org/10.3390/microorganisms9112281] [PMID:  34835406]

[16]
Zhang H, Chen Y, Wang Z, et al. Implications of gut microbiota in neurodegenerative diseases. Front Immunol  2022; 13: 785644.
 [http://dx.doi.org/10.3389/fimmu.2022.785644] [PMID:  35237258]

[17]
Nagao-Kitamoto H, Kitamoto S, Kuffa P, Kamada N. Pathogenic role of the gut microbiota in gastrointestinal diseases. Intest Res  2016; 14(2): 127-38.
 [http://dx.doi.org/10.5217/ir.2016.14.2.127] [PMID:  27175113]

[18]
Yan Q, Gu Y, Li X, et al. Alterations of the gut microbiome in hypertension. Front Cell Infect Microbiol  2017; 7: 381.
 [http://dx.doi.org/10.3389/fcimb.2017.00381] [PMID:  28884091]

[19]
Jayasinghe TN, Chiavaroli V, Holland DJ, Cutfield WS, O’Sullivan JM. The new era of treatment for obesity and metabolic disorders: Evidence and expectations for gut microbiome transplantation. Front Cell Infect Microbiol  2016; 6: 15.
 [http://dx.doi.org/10.3389/fcimb.2016.00015] [PMID:  26925392]

[20]
Lim YY, Lee YS, Ooi DSQ. Engineering the gut microbiome for treatment of obesity: A review of current understanding and progress. Biotechnol J  2020; 15(10): 2000013.
 [http://dx.doi.org/10.1002/biot.202000013] [PMID:  32663372]

[21]
Muscogiuri G, Cantone E, Cassarano S, et al. on behalf of the Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group. Gut microbiota: A new path to treat obesity. Int J Obes Suppl  2019; 9(1): 10-9.
 [http://dx.doi.org/10.1038/s41367-019-0011-7] [PMID:  31391921]

[22]
Jiang H, Cai M, Shen B, Wang Q, Zhang T, Zhou X. Synbiotics and gut microbiota: New perspectives in the treatment of type 2 diabetes mellitus. Foods  2022; 11(16): 2438.
 [http://dx.doi.org/10.3390/foods11162438] [PMID:  36010438]

[23]
Zhang L, Chu J, Hao W, et al.  Gut microbiota and type 2 diabetes mellitus: Association, mechanism, and translational applications. Mediators of Inflammation 2021; 2021

[24]
Andrade S, Borges N. Effect of fermented milk containing Lactobacillus acidophilus and Bifidobacterium longum on plasma lipids of women with normal or moderately elevated cholesterol. J Dairy Res  2009; 76(4): 469-74.
 [http://dx.doi.org/10.1017/S0022029909990173] [PMID:  19825213]

[25]
Varesi A, Pierella E, Romeo M, et al. The potential role of gut microbiota in Alzheimer’s disease: From diagnosis to treatment. Nutrients  2022; 14(3): 668.
 [http://dx.doi.org/10.3390/nu14030668] [PMID:  35277027]

[26]
Nishikawa M, Brickman AM, Manly JJ, Schupf N, Mayeux RP, Gu Y. Dietary prebiotic consumption is associated with reduced risk of Alzheimer’s disease in a multiethnic population. Curr Alzheimer Res  2021; 18(12): 984.
 [http://dx.doi.org/10.2174/1567205019666211222115142] [PMID:  34951365]

[27]
Barbosa RSD, Vieira-Coelho MA. Probiotics and prebiotics: Focus on psychiatric disorders: A systematic review. Nutr Rev  2020; 78(6): 437-50.
 [http://dx.doi.org/10.1093/nutrit/nuz080] [PMID:  31769847]

[28]
Lilly DM, Stillwell RH. Probiotics: growth-promoting factors produced by microorganisms. Science  1965; 147(3659): 747-8.
 [http://dx.doi.org/10.1126/science.147.3659.747] [PMID:  14242024]

[29]
Martinowich K, Lu B. Interaction between BDNF and serotonin: Role in mood disorders. Neuropsychopharmacology  2008; 33(1): 73-83.
 [http://dx.doi.org/10.1038/sj.npp.1301571] [PMID:  17882234]

[30]
Agahi A, Hamidi GA, Daneshvar R, et al. Does severity of Alzheimer’s disease contribute to its responsiveness to modifying gut microbiota? A double blind clinical trial. Front Neurol  2018; 9: 662.
 [http://dx.doi.org/10.3389/fneur.2018.00662] [PMID:  30158897]

[31]
Masino SA, Rho JM. Mechanisms of ketogenic diet action. Epilepsia  2010; 51(s5): 85-5.
 [http://dx.doi.org/10.1111/j.1528-1167.2010.02871.x]

[32]
Bostock ECS, Kirkby KC, Taylor BVM. The current status of the ketogenic diet in psychiatry. Front Psychiatry  2017; 8: 43.
 [http://dx.doi.org/10.3389/fpsyt.2017.00043] [PMID:  28373848]

[33]
Zhu M, Liu X, Ye Y, et al. Gut Microbiota: A novel therapeutic target for Parkinson’s disease. Front Immunol  2022; 13: 937555.
 [http://dx.doi.org/10.3389/fimmu.2022.937555] [PMID:  35812394]

[34]
Georgescu D, Ancusa O, Georgescu L, Ionita I, Reisz D. Nonmotor gastrointestinal disorders in older patients with Parkinson’s disease: Is there hope? Clin Interv Aging  2016; 11: 1601-8.
 [http://dx.doi.org/10.2147/CIA.S106284] [PMID:  27956826]

[35]
Liu X, Du ZR, Wang X, et al. Polymannuronic acid prebiotic plus Lacticaseibacillus rhamnosus GG probiotic as a novel synbiotic promoted their separate neuroprotection against Parkinson’s disease. Food Res Int  2022; 155: 111067.
 [http://dx.doi.org/10.1016/j.foodres.2022.111067] [PMID:  35400445]

[36]
Chen ZJ, Liang CY, Yang LQ, et al. Association of Parkinson’s disease with microbes and microbiological therapy. Front Cell Infect Microbiol  2021; 11: 619354.
 [http://dx.doi.org/10.3389/fcimb.2021.619354] [PMID:  33763383]

[37]
Barichella M, Cereda E, Cassani E, et al. Dietary habits and neurological features of Parkinson’s disease patients: Implications for practice. Clin Nutr  2017; 36(4): 1054-61.
 [http://dx.doi.org/10.1016/j.clnu.2016.06.020] [PMID:  27406858]

[38]
Kraeuter A-K, Guest P C, Sarnyai Z. The therapeutic potential of ketogenic diet throughout life: Focus on metabolic, neurodevelopmental and neurodegenerative disorders. Reviews on Biomarker Studies in Aging and Anti-Aging Research  2019; 77-101.

[39]
Bayliss JA, Lemus MB, Stark R, et al. Ghrelin-AMPK signaling mediates the neuroprotective effects of calorie restriction in Parkinson’s disease. J Neurosci  2016; 36(10): 3049-63.
 [http://dx.doi.org/10.1523/JNEUROSCI.4373-15.2016] [PMID:  26961958]

[40]
Fu W, Zhuang W, Zhou S, Wang X. Plant-derived neuroprotective agents in Parkinson’s disease. Am J Transl Res  2015; 7(7): 1189-202.
 [PMID:  26328004]

[41]
Zhang YJ, Li S, Gan RY, Zhou T, Xu DP, Li HB. Impacts of gut bacteria on human health and diseases. Int J Mol Sci  2015; 16(12): 7493-519.
 [http://dx.doi.org/10.3390/ijms16047493] [PMID:  25849657]

[42]
Tsoi H, Chu ES, Zhang X, et al. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice. Gastroenterology  2017; 152(6): 1419-33.
 [http://dx.doi.org/10.1053/j.gastro.2017.01.009]

[43]
Wong SH, Zhao L, Zhang X, et al. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology  2017; 153(6): 1621-33.
 [http://dx.doi.org/10.1053/j.gastro.2017.08.022]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0118715265267536231121095634	Print ISSN 1871-5265
Publisher Name Bentham Science Publisher	Online ISSN 2212-3989

Infectious Disorders - Drug Targets

Different Strategies Targeting Gut Microbiota for the Management of Several Disorders: A Sustainable Approach

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract